This test is most useful if any of these apply to you.
A standard cholesterol test tells you how much cholesterol is in your blood. It does not show how many particles carry that cholesterol, check for inflammation linked to the arteries, measure Lp(a), a largely inherited particle, or reveal how hard your body is working to control blood sugar.
This panel adds those missing pieces to a standard lipid panel, all from a single blood draw. Read together, the results map where your risk sits today and give you a baseline to track as you make changes.
The results fall into four groups: cholesterol and the particles that carry it, inflammation, blood sugar and insulin, and a cholesterol balance reading that shows whether your body leans toward making or absorbing cholesterol.
Total cholesterol, HDL cholesterol, and triglycerides sketch the outline, and LDL cholesterol is measured directly rather than estimated. Every particle that can get trapped in an artery wall and build plaque carries exactly one apolipoprotein B (apoB) protein, so apoB is a direct measure of how many of these particles you have. LDL makes up about 90% of these particles, and an expert working group stated that apoB measures LDL particle number better than LDL cholesterol does.
Small dense LDL cholesterol (sdLDL-C) is the cholesterol carried in the smallest, densest LDL particles, the ones most prone to building plaque. High triglycerides help these particles form. In the Multi-Ethnic Study of Atherosclerosis, high sdLDL-C identified coronary heart disease risk that standard lipid measures missed, though only in people without diabetes or raised fasting glucose.
Apolipoprotein A-I (apoA-I) gives HDL particles their structure and activates enzymes that attach a fatty acid to cholesterol so it can move into the HDL core. A low level is associated with higher cardiovascular risk. Lipoprotein(a), or Lp(a), is an LDL-like particle with an extra protein, apolipoprotein(a), attached. The American Heart Association describes high Lp(a) as an independent and causal risk factor, with most of the difference between people set by genes.
High-sensitivity C-reactive protein (hs-CRP) is an inflammation protein made by the liver, measured at the very low levels that may be seen with inflammation in blood vessels or elsewhere in the body. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is more specific to the arteries. This enzyme, made by immune cells called monocytes and macrophages, reflects active inflammation in the vessel wall. Higher activity is associated with soft, actively growing plaque rather than stable, calcified plaque, and it predicts risk independent of LDL cholesterol.
HbA1c measures the glucose attached to hemoglobin in red blood cells, which reflects your average blood sugar over the last two to three months. Fasting glucose is a snapshot of one moment. Insulin is the hormone your pancreas makes to move glucose into cells, and C-peptide is released alongside it by the pancreas's insulin-making beta cells. Together they show how hard your body is working to keep glucose in range. C-peptide stays an accurate measure of your own insulin production even if you take insulin.
Fasting glucose and insulin are combined into HOMA-IR, a standard estimate of insulin resistance from one fasting sample. When cells resist insulin, the beta cells can work much harder to hold glucose steady. Over time they can become progressively impaired, potentially leading to prediabetes and then type 2 diabetes. In a large study of postmenopausal women whose fasting glucose was still below the diabetes range, HOMA-IR was more strongly linked to new diabetes than glucose or insulin alone.
This part of the panel measures four sterols, molecules closely related to cholesterol. Lathosterol and desmosterol are building blocks your body makes on the way to cholesterol, so they mark production. Campesterol and beta-sitosterol are plant sterols that come only from food, so they mark absorption: their levels in your blood reflect how much your gut absorbs. Each appears twice, as an absolute amount and normalized to your total cholesterol. The Cholesterol Balance Score divides production by absorption: below 0.5 points to an over-absorber, 0.5 to 1.1 is balanced, and above 1.1 points to an over-producer.
Many of these markers move together, so they are most useful read as a set. High triglycerides help form small dense LDL and contribute to low levels of large HDL particles. Low HDL cholesterol is a characteristic of insulin resistance, so your lipids can hint at how your body is handling insulin.
| Pattern | What It May Suggest |
|---|---|
| Normal LDL cholesterol but high apoB or sdLDL-C | More, or denser, plaque-building particles than the cholesterol number alone suggests |
| High triglycerides, low HDL cholesterol, and high insulin or HOMA-IR | A pattern associated with insulin resistance, which can show up before glucose or HbA1c look abnormal |
| Cholesterol Balance Score above 1.1 or below 0.5 | Your body leans toward overproducing (above 1.1) or over-absorbing (below 0.5) cholesterol, which can guide how a clinician approaches lowering LDL |
| Normal standard lipids but high Lp(a), hs-CRP, or Lp-PLA₂ | Inherited or inflammatory risk that a routine cholesterol panel does not measure. A high hs-CRP counts here only once a recent illness or injury is ruled out. |
An out-of-range result is a prompt for a conversation with your clinician. The panel is designed to help guide treatment decisions, and lifestyle change is the cornerstone of lowering heart disease and diabetes risk. A cardiologist, lipid specialist, or primary care clinician can weigh these results alongside your blood pressure and family history, and can use the cholesterol production and absorption markers to choose an LDL-lowering approach that fits how your body handles cholesterol.
To see whether a change is working, repeat the panel after a shift in diet, activity, or treatment, on a schedule your clinician sets. Your hs-CRP may also help show how well you are responding to lifestyle change and statin treatment. In the JUPITER statin trial, people taking the statin who reached the trial's cutoffs for both LDL cholesterol and hs-CRP had a larger drop in cardiovascular events than those who reached one or neither. Lp(a), by contrast, is largely inherited and tends to stay stable.
Boston Heart CVMap & Metabolics is best interpreted alongside these tests.